Table 1.

Clinical Characteristics of Patients with Diffuse Large-B-Cell Lymphoma Treated with R-CHOP.^*

Characteristic	All Subtypes (N = 233)	Germinal Center B-Cell–like Subtype (N = 107)	Activated B-Cell–like Subtype (N = 93)	Unclassified Subtype (N = 33)	P Value†
	no./total no. (%)
Age >60 yr	122/233 (52)	50/107 (47)	59/93 (63)	13/33 (39)	0.023
Ann Arbor stage >II‡	121/226 (54)	49/103 (48)	56/91 (62)	16/32 (50)	0.061
Lactate dehydrogenase >ULN	93/192 (48)	38/89 (43)	44/76 (58)	11/27 (41)	0.062
≥2 Extranodal sites	30/204 (15)	13/92 (14)	13/84 (15)	4/28 (14)	0.834
ECOG performance status >1§	52/210 (25)	17/98 (17)	27/82 (33)	8/30 (27)	0.023
IPI score¶					<0.001
0 or 1	75/182 (41)	47/85 (55)	15/71 (21)	13/26 (50)
2 or 3	83/182 (46)	28/85 (33)	45/71 (63)	10/26 (38)
4 or 5	24/182 (13)	10/85 (12)	11/71 (15)	3/26 (12)

^*R-CHOP denotes rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone, and ULN upper limit of the normal range.

^†P values are for the comparison of activated B-cell–like and germinal-center B-cell–like diffuse large-B-cell lymphomas.

^‡The Ann Arbor staging system ranges from I to IV, with a higher stage indicating more widespread disease.

^§The Eastern Cooperative Oncology Group (ECOG) performance score ranges from 0 to 3, with a higher score indicating greater impairment.

^¶The International Prognostic Index (IPI) score ranges from 0 to 5, with 0 indicating the absence of all prognostic factors and 5 indicating the presence of all prognostic factors.